Amplo Biotechnology
La Jolla
About Amplo Biotechnology
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.1M
- Funding stage: Seed
- Last round: Grant (Jan 2025)
- Website: amplobiotechnology.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics
Canonical: https://fsome.com/organization/amplo-biotechnology-843 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.